Sequential design of phase II-III cancer trials.

about

ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation The need for thorough phase II studies in medicines development for Alzheimer's disease.Developing biomarker-specific end points in lung cancer clinical trials.

P2860

Q35187185-B04AB96F-A7E3-4C7E-ADB1-26FDF74EF2FA Q36206793-37D8147F-4BEA-4F10-B539-325349355D6D Q38297892-7AC8BB1F-6FF9-4BA6-8A52-63ACEBF18E0E

P2860

Sequential design of phase II-III cancer trials.

Item

http://www.wikidata.org/entity/Q35940107

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Sequential design of phase II-III cancer trials.

@ast

Sequential design of phase II-III cancer trials.

@en

type

Item

label

Sequential design of phase II-III cancer trials.

@ast

Sequential design of phase II-III cancer trials.

@en

prefLabel

Sequential design of phase II-III cancer trials.

@ast

Sequential design of phase II-III cancer trials.

@en

P1476

Sequential design of phase II-III cancer trials.

@en

P2093

Mei-Chiung Shih

http://www.w3.org/2001/XMLSchema#string

Philip W Lavori

http://www.w3.org/2001/XMLSchema#string

Tze Leung Lai

http://www.w3.org/2001/XMLSchema#string

P2860

Can the pharmaceutical industry reduce attrition rates?

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Admissible two-stage designs for phase II cancer clinical trials.

Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing.

Using short-term response information to facilitate adaptive randomization for survival clinical trials

Adaptive two-stage designs in phase II clinical trials.

A review of phase 2-3 clinical trial designs.

Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.

Randomized phase II designs.

P304

1944-1960

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/SIM.5346

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221709336

http://www.w3.org/2001/XMLSchema#string

P698

22422502

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

phase III clinical trial

P932

4532356

http://www.w3.org/2001/XMLSchema#string

Sequential design of phase II-III cancer trials.

about

P2860

P2860

Sequential design of phase II-III cancer trials.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932